Azafaros Announces Key Scientific Oral and Poster Presentations on Nizubaglustat Accepted for WORLDSymposium™ 2025.

Atea Pharmaceuticals (AVIR) announced it presented three poster presentations supporting the combination of bemnifosbuvir and ruzasvir as a ...

Ruvindu Perera, cell and molecular biology graduate student, placed first in the Foodborne Pathogens and Contaminants in Animal-Based Products category. Amanda Anthney, poultry science graduate ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and ...

Atea Pharmaceuticals (AVIR) announced it presented three poster presentations supporting the combination of bemnifosbuvir and ruzasvir as a potential treatment for hepatitis C virus, or HCV.

The conference brings together industry and academic professionals to explore the rapidly advancing science and business of mRNA medicines and features poster presentations highlighting the latest ...

The poster presentation details are as follows: Session Name: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster II Publication Number: 2881 Title: MP0533 (CD33 x ...

Poster presentations across all programs, including updates from ongoing clinical studies and new translational data in ...

allowing for control of tumors in vivo without the need for exogenous or engineered cytokines- - Posters include demonstration of advances in gene editing and transgene design that enable greater ...

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today ...

SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage ...